{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06400004",
            "orgStudyIdInfo": {
                "id": "BR1-149"
            },
            "organization": {
                "fullName": "Bracco Diagnostics, Inc",
                "class": "INDUSTRY"
            },
            "briefTitle": "Lumason\u00ae Infusion vs. Bolus Administrations",
            "officialTitle": "A Phase III Crossover Study to Evaluate Bolus Versus Continuous Infusion of Lumason\u00ae in Patients With Suboptimal Unenhanced Echocardiography",
            "therapeuticArea": [
                "Cardiovascular"
            ],
            "study": "lumason-infusion-vs-bolus-administrations"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-04",
            "overallStatus": "NOT_YET_RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-04-30",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-07-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-12-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-04-23",
            "studyFirstSubmitQcDate": "2024-05-01",
            "studyFirstPostDateStruct": {
                "date": "2024-05-06",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-05-01",
            "lastUpdatePostDateStruct": {
                "date": "2024-05-06",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Bracco Diagnostics, Inc",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "A phase III study designed as a randomized, within-patient comparison of continuous infusion of diluted Lumason\u00ae versus the bolus administration of undiluted Lumason\u00ae for degree of LVO and assessment of LV EBD (co-primary endpoints).",
            "detailedDescription": "This is a phase III study designed as a randomized, within-patient comparison of continuous infusion of diluted Lumason\u00ae versus the bolus administration of undiluted Lumason\u00ae for degree of LVO and assessment of LV EBD (co-primary endpoints). The study will enroll patients with suboptimal LV EBD defined as \u22652 adjacent segments in any apical view that cannot be visualized at pre-contrast echocardiogram."
        },
        "conditionsModule": {
            "conditions": [
                "Heart Diseases"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE3"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "CROSSOVER",
                "primaryPurpose": "DIAGNOSTIC",
                "maskingInfo": {
                    "masking": "SINGLE",
                    "whoMasked": [
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 106,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Bolus administration",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "Bolus administration of 2 mL undiluted Lumason\u00ae",
                    "interventionNames": [
                        "Drug: Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Injection Powder for Suspension [LUMASON]"
                    ]
                },
                {
                    "label": "Continuous infusion",
                    "type": "EXPERIMENTAL",
                    "description": "Continuous infusion of 8 mL of diluted Lumason\u00ae",
                    "interventionNames": [
                        "Drug: Lumason"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Injection Powder for Suspension [LUMASON]",
                    "description": "Bolus administration of 2 mL undiluted Lumason\u00ae, to be administered in 20 seconds",
                    "armGroupLabels": [
                        "Bolus administration"
                    ],
                    "otherNames": [
                        "Bolus Administration"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Lumason",
                    "description": "Continuous infusion of 8 mL of diluted Lumason\u00ae (4 mL of Lumason\u00ae diluted in 4 mL of saline) at a rate of 1.0 mL/min",
                    "armGroupLabels": [
                        "Continuous infusion"
                    ],
                    "otherNames": [
                        "Infusion Administration"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Adequate LV EBD Score",
                    "description": "Compare the proportion of patients with adequate LV EBD score for infusion vs. bolus administrations in patients with suboptimal left ventricular endocardial border delineation at unenhanced echocardiography.",
                    "timeFrame": "2-3 Hours"
                },
                {
                    "measure": "Adequate LV Opacification",
                    "description": "Compare the proportion of patients with adequate LV opacification for infusion vs. bolus administrations in patients with suboptimal left ventricular endocardial border delineation at unenhanced echocardiography.",
                    "timeFrame": "2-3 Hours"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Clinically useful LVO",
                    "description": "To compare the duration of clinically useful LVO in infusion vs. bolus administrations in terms of duration",
                    "timeFrame": "2-3 Hours"
                },
                {
                    "measure": "Adverse events",
                    "description": "Compare adverse event rate after infusion vs. bolus administrations",
                    "timeFrame": "24 Hours"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Are at least 18-years old;\n* Have suboptimal LV EBD, defined as \u22652 adjacent segments in any apical view that cannot be visualized, at pre-contrast echocardiogram;\n* Provide their written informed consent and are willing to comply with protocol requirements.\n\nExclusion Criteria:\n\n* Patient has severe congestive heart failure (class IV according to the classification of the New York Heart Association);\n* Patient has uncontrolled angina (i.e., uncontrolled on medication);\n* Patient had a recent myocardial infarction (within the last 3 days and not stabilized);\n* Patient has severe arrhythmia, that in the opinion of the Investigator, would interfere with the study conduct;\n* Patient has severe pulmonary hypertension, that in the opinion of the Investigator, would interfere with the study conduct;\n* Patient had been treated with any other contrast medium, either intravascular or orally, within 48 hours prior to the first administration;\n* Has any known allergy to one or more of the ingredients of the investigational product;\n* Is pregnant or lactating. Exclude the possibility of pregnancy by: testing on site (serum or urine \u03b2HCG) prior to the start of investigational product administration; surgical history (e.g., tubal ligation or hysterectomy); post-menopausal with a minimum 1 year without menses;\n* Has previously entered the study or have received any other investigational drug within 30 days prior to admission in this study;\n* Is determined by the Investigator that the patient is clinically unsuitable for the study.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Rushil Sankpal",
                    "role": "CONTACT",
                    "phone": "609-514-2267",
                    "email": "rushil.sankpal@diag.bracco.com"
                },
                {
                    "name": "Audrey Sahns",
                    "role": "CONTACT",
                    "phone": "610-357-1734",
                    "email": "audrey.sahns@diag.bracco.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Jose Banchs, MD",
                    "affiliation": "Sr. Medical Director",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Piedmont Heart Institute",
                    "city": "Atlanta",
                    "state": "Georgia",
                    "zip": "30309",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Caryn Bernstein",
                            "role": "CONTACT",
                            "phone": "404-605-5688",
                            "email": "caryn.bertstein@piedmont.org"
                        },
                        {
                            "name": "Venkateshwar Polsani, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.749,
                        "lon": -84.38798
                    }
                },
                {
                    "facility": "Beth Israel Deaconess Medical Center",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02215",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Constance Angell-James, MPH",
                            "role": "CONTACT",
                            "email": "cangellj@bidmc.harvard.edu"
                        },
                        {
                            "name": "Madeline Cassidy",
                            "role": "CONTACT",
                            "email": "mcassid6@bidmc.harvard.edu"
                        },
                        {
                            "name": "Jordan Strom, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                },
                {
                    "facility": "Oregon Health and Sciences University",
                    "city": "Portland",
                    "state": "Oregon",
                    "zip": "97239",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Kevin Wei, MD",
                            "role": "CONTACT",
                            "phone": "503-494-7400",
                            "email": "weik@ohsu.edu"
                        },
                        {
                            "name": "Kevin Wei, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 45.52345,
                        "lon": -122.67621
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000006331",
                    "term": "Heart Diseases"
                }
            ],
            "ancestors": [
                {
                    "id": "D000002318",
                    "term": "Cardiovascular Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M9419",
                    "name": "Heart Diseases",
                    "asFound": "Heart Disease",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC14",
                    "name": "Heart and Blood Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        }
    },
    "hasResults": false
}